← Oncology Approval Tracker

FDA DECISION ·

Opdivo and Opdivo Qvantig

nivolumab (IV or with hyaluronidase-nvhy SC) · Bristol Myers Squibb

FDA approvalIndication revisionGastric, gastroesophageal junction and esophageal adenocarcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Limits nivolumab with fluoropyrimidine and platinum chemotherapy to adults with advanced or metastatic gastric cancer, GEJ cancer, or esophageal adenocarcinoma whose tumors express PD-L1 at least 1.

LAMPGEN ANALYSIS

Why it matters

The revised eligibility criteria apply to the chemotherapy combination with either nivolumab formulation in this gastroesophageal adenocarcinoma setting.

What research teams should watch

Update patient selection templates for the PD-L1 threshold and ensure the route-specific administration order matches the intended regimen.

PRIMARY RECORDS

Sources